



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 26 2002

TECH CENTER 1600/2900

In re PATENT APPLICATION OF

Hanna et al.

Group Art Unit: 1644

Application No. 09/855,717

Examiner: P. Gambel

Filed: May 16, 2001

Title: Treatment of B-Cell Malignancies Using Combination of B Cell Depleting Antibody and Immune Modulating Antibody Related Applications

#6
JMY
11/26/02

November 21, 2002

ELECTION RESPONSE

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action [Restriction Requirement] mailed on September 30, 2002, Applicants elect with traverse Group I, claims 1-41 and 57-103, drawn to methods of treating malignancies by administering CD40L-specific antibodies in combination therapies. The traversal is on the basis that the search for the non-elected claims, which are directed to therapeutic compositions useful in the method of Group I, would be substantially co-extensive with the elected subject matter.

If the examiner has any questions relating to this application, he is respectfully requested to contact the undersigned at the telephone number given below.

By: _____

Robin L. Teskin

Registration No. 35,030

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2200
(703) 905-2500 Facsimile

11/22/2002 WMOHAMM1 00000151 033975 09855717 M

01 FC:1251

110.00 CH